Asia Executives On The Move: Sanofi, GSK, Merck
The coming of spring has brought with it a plethora of pharma executives changes in the Asia Pacific. Sanofi has a new China GM, Merck China R&D head leaves for a startup and Daiichi Sankyo has a new head for its generics business.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.